Vertex Pharmaceuticals, Inc.

David Smith

John R Studley

Benjamin Joseph Littler

Robert Michael Hughes

Paul Angell

Berenice Lewandowski

David Andrew Siesel

Vito Melillo

William Aloysius Nugent

Cristian Harrison

Patricia Nell Hurter

Martin Paul Warman

Vance Hayden Thomas

David E Nadig

Kelly Ann Swinney

William A Nugent

Paul T Angell

John Studley

The disclosure provides processes for preparing a compound of Formula (I):

Processes for making modulators of cystic fibrosis transmembrane conductance regulator

The disclosure provides processes for preparing a compound of Formula (I). 

Processes for preparing 5,5-dimethyl-3-methylenepyrrolidin-2-one, (S)-3,5,5-trimethylpyrrolidine-2-one, (R)-3,5,5-trimethylpyrrolidine-2-one, (S)-2,4,4-trimethylpyrrolidine, and (R)-2,4,4-trimethylpyrrolidine, and their salt forms are disclosed. 

Processes for preparing pyrrolidine compounds

Processes of preparing pharmaceutical compositions comprising 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (Compound 1) in Form I and a solid dispersion comprising substantially amorphous N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1H-quinoline-3-carboxamide (Compound 2), methods of treating, lessening the severity of or symptomatically treating CFTR mediated diseases, such as cystic fibrosis, methods of administering, and kits thereof are disclosed.

Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseases

Growing community of inventors

Newton, MA, United States of America

David Smith